SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
Virdee P., Shaw RA., Strauss VY., Hamill CE., Hurt CN., Corrie P., Bridgewater J., Parsons P., Tranter B., Sebag-Montefiore D., Chu K-Y., Radhakrishna G., Hawkins M., O'Neill EE., Campbell S., Love SB., Maughan TS., Mukherjee S.
Chemotherapy followed by consolidation chemoradiotherapy (CRT) is a treatment option for locally advanced non-metastatic pancreatic cancer (LAPC), but outcome remains poor. The SCALOP trial identified a feasible, safe, and effective CRT regimen for LAPC: capecitabine (830mg/m2 oral bd) as radiosensitisation + 50.4Gy in 28 fractions. The two-stage SCALOP-2 trial aims to improve this regimen by increasing radiotherapy dose intensity and adding nelfinavir as an additional radiosensitising AKT inhibitor.